Recent Drug Developments and Law Update

Recent Drug Developments and Law Update 2024 will be held Sunday, March 3rd, 7:45 AM-1:30 PM Hosted remotely via Zoom.

PLEASE NOTE: This 5 hour program is being offered as group continuing education attended individually on a personal computer or mobile device.

REGISTRATION CLOSED on March 1st, 5:00 PM
CANCELLATION POLICY: No refunds after February 28th 

Registration Schedule

Presentations - Sunday March 3rd, 2024

Description

New drugs and new guideline recommendations continue to affect medical practice.  This program will provide updates on management of heart failure with reduced ejection fraction (HFrEF) and treatment of pain and other care recommendations for end of life.  Current recommendations for the respiratory syncytial virus vaccine will be presented.  In addition, an update from the Montana Board of Pharmacy will be provided. 

Goal

The goal of this program is to discuss new drugs, to compare them to other agents in the same pharmacological and/or therapeutic class, and to discuss where these new agents fit into disease state management.  In addition, an update of federal and Montana state pharmacy laws will be provided

Objectives

At the conclusion of this program, the participant should be able to:

  • Explain common and rare complications of respiratory syncytial virus (RSV)
  • Select appropriate RSV vaccination recommendations for a specific patient
  • Explain the Guideline Directed Medical Therapy, Class I, Level of Evidence A (i.e., first-line drugs) to manage heart failure with reduced ejection fraction (HFrEF) patients in the outpatient setting
  • Develop a medication treatment plan and optimize the titration of the heart failure medications discussed in patients with a diagnosis of HFrEF
  • List legislative and regulatory changes impacting the practice of pharmacy in Montana
  • Discuss Red Tape Relief efforts to update existing regulations/rules
  • Recommend one opioid patch appropriate for use and another patch not recommended for pain management at the end of life
  • Explain the safe use and disposal of controlled medications in the home
  • Describe the evidence supporting buprenorphine for opioid use disorder
  • Explain the complexities of buprenorphine prescribing in the age of fentanyl

 

Activity Type: Knowledge-based

Target Audience: Pharmacists & Pharmacy Technicians (law portion only)

Accreditation Information

ACPE_logo.jpg
Skaggs School of Pharmacy at The University of Montana is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based activity. The Universal Activity Number (UAN) for the Recent Drug Development portion is #0035-0000-24-014-L01-P, and approved for 4 hours or 0.40 CEUs for Pharmacists. The Universal Activity Number for the Recent Law portion is #0035-0000-24-015-L03-P/T, and approved for 1 hour or 0.10 CEUs for Pharmacists and Pharmacy Technicians. In order to receive credits, participants must sign in to the presentation, view the entire presentation, and complete the program evaluation. CE credits will be uploaded to CPE Monitor within 60-days after the program.

Disclosure

Disclosure of Potential Conflicts of Interest: Skaggs School of Pharmacy at The University of Montana did not receive payment or services from a third party for any aspect of this activity and has no relationships (financial or other) with entities or activities that could be perceived to influence, or that give the appearance of potentially influencing any portion of this activity.

Program Coordinator

Sherrill Brown, DVM, Pharm. D., BCPS
Director, Drug Information Service
The University of Montana, College of Health

Speakers

Vince Colucci, PharmD, BCPS (Cardiology), AACC, CPP

Rose Macklin, PharmD, BCPS

Marcie Bough, PharmD

Brett Bell, MD, MPH

Ken Chatriand, PharmD

Contact us

E-mail: pharmacy.ce@umontana.edu

Launch UM virtual tour.